☆ 4.7 Letter

Validation of cytogenetic-based risk stratification in primary myelofibrosis

BLOOD (2010)

Journal

BLOOD

Volume 115, Issue 13, Pages 2719-2720

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2009-12-258988

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping

Alvaro Diaz-Gonzalez, Elvira Mora, Gayane Avetisyan, Santiago Furio, Rosalia De la Puerta, Jose Vicente Gil, Alessandro Liquori, Eva Villamon, Carmen Garcia-Hernandez, Marta Santiago, Cristian Garcia-Ruiz, Marta Llop, Blanca Ferrer-Lores, Eva Barragan, Silvia Garcia-Palomares, Empar Mayordomo, Irene Luna, Ana Vicente, Lourdes Cordon, Leonor Senent, Alberto Alvarez-Larran, Jose Cervera, Javier De la Rubia, Juan Carlos Hernandez-Boluda, Esperanza Such

Summary: Cytogenetic assessment is crucial for myelofibrosis patients, but traditional techniques often fail to provide useful karyotypes. This study introduces optical genome mapping (OGM) as a promising method for high-resolution evaluation of chromosomal aberrations. OGM, combined with NGS, enabled risk classification in all cases, identifying additional cryptic aberrations and upgrading risk categories. The study highlights OGM as a valuable tool to improve disease risk stratification in myelofibrosis patients.

CANCERS (2023)

Add to Collection

Review Medicine, General & Internal

Risk Stratification in Primary Biliary Cholangitis

Francesco Martini, Daniele Balducci, Martina Mancinelli, Valerio Buzzanca, Elena Fracchia, Giuseppe Tarantino, Antonio Benedetti, Marco Marzioni, Luca Maroni

Summary: Primary Biliary Cholangitis (PBC) is a liver disease with a varied presentation, progression, and response to treatment. Current risk assessment relies on analyzing demographic data, clinical findings, antibody profiles, and liver fibrosis evaluation to identify patients at higher risk of disease progression. The response to therapy after one year remains a significant factor influencing the prognosis of PBC patients. Tailored treatment strategies are emerging to replace the one-size-fits-all approach, requiring the development of risk prediction models to assess patients' course, outcome, and response to treatment at the time of diagnosis. This review provides an overview of current and emerging risk stratification tools and speculates on their potential impact on PBC management.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Oncology

Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma

Jiehui Tan, Man Shu, Junbin Liao, Ruiming Liang, Shiyi Liu, Ming Kuang, Sui Peng, Han Xiao, Qian Zhou

Summary: The study aimed to identify plasma metabolomic biomarkers for preoperative risk stratification of intrahepatic cholangiocarcinoma (ICC) patients. The LASSO-Cox prediction model was constructed and showed potential in evaluating overall survival (OS) of ICC patients after surgical resection, providing reference for optimal treatment options.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Development and Validation of Multi-Omics Thymoma Risk Classification Model Based on Transfer Learning

Wei Liu, Wei Wang, Hanyi Zhang, Miaoran Guo, Yingxin Xu, Xiaoqi Liu

Summary: The study aimed to develop a prediction model that combines clinical, radiomics, and deep features to stratify the risk level of thymoma using transfer learning. The study enrolled 150 thymoma patients who underwent surgical resection and pathology confirmation. Features were extracted from CT images, and statistical methods were used for feature selection. A fusion model integrating clinical, radiomics, and deep features was developed, and its performance was evaluated using various metrics. The fusion model outperformed the clinical, radiomics, and deep models in stratifying high and low risk of thymoma.

JOURNAL OF DIGITAL IMAGING (2023)

Add to Collection

Article Hematology

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management

Ayalew Tefferi

Summary: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, with common features including bone marrow fibrosis, abnormal inflammatory cytokine expression, anemia, hepatosplenomegaly, etc. Diagnosis is primarily based on bone marrow morphology. Treatment strategies can vary based on risk stratification, with options such as observation, drug therapy, or hematopoietic stem cell transplant.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Ayalew Tefferi

Summary: Primary myelofibrosis is a stem cell-derived disorder characterized by clonal myeloproliferation, fibrosis, and other symptoms. Diagnosis is made through bone marrow examination and genetic testing. Treatment options mainly involve drug therapy, and new agents are under investigation.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Identification and validation of a prognostic risk-scoring model based on sphingolipid metabolism-associated cluster in colon adenocarcinoma

Qihang Yuan, Weizhi Zhang, Weijia Shang

Summary: This study investigated the effects of sphingolipid metabolism-related genes on human cancers, specifically colon adenocarcinoma (COAD). Through analysis of gene data, the study found that sphingolipid metabolism is closely associated with the development and prognosis of COAD. A prognostic model based on sphingolipid metabolism was developed to quantitatively evaluate clinical outcomes.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Focus on Osteosclerotic Progression in Primary Myelofibrosis

Mariarita Spampinato, Cesarina Giallongo, Alessandra Romano, Lucia Longhitano, Enrico La Spina, Roberto Avola, Grazia Scandura, Ilaria Dulcamare, Vincenzo Bramanti, Michelino Di Rosa, Nunzio Vicario, Rosalba Parenti, Giovanni Li Volti, Daniele Tibullo, Giuseppe A. Palumbo

Summary: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by clonal proliferation of hematopoietic stem cells leading to bone marrow fibrosis. The main consequences of PMF include neoangiogenesis, megakaryocytes hyperplasia, extensive bone marrow fibrosis, osteosclerosis, and bone damage. The involvement of cytokines, growth factors, and resident cells in the bone marrow microenvironment are linked to disease progression in PMF.

BIOMOLECULES (2021)

Add to Collection

Article Multidisciplinary Sciences

Validation of an admission coagulation panel for risk stratification of COVID-19 patients

Darwish Alabyad, Srikant Rangaraju, Michael Liu, Rajeel Imran, Christine L. Kempton, Milad Sharifpour, Sara C. Auld, Manila Gaddh, Roman Sniecinski, Cheryl L. Maier, Jeannette Guarner, Alexander Duncan, Fadi Nahab

Summary: MOCHA parameters are useful for risk-stratifying COVID-19 patients for thrombotic complications, and more effective than isolated D-dimer in predicting the risk of ICU admission and intubation.

PLOS ONE (2021)

Add to Collection

Article Computer Science, Information Systems

Development and validation of colorectal cancer risk prediction tools: A comparison of models

Duco T. Mulder, Rosita van den Puttelaar, Reinier G. S. Meester, James F. O'Mahony, Iris Lansdorp-Vogelaar

Summary: By using logistic regression and random forest models to predict the risk of colorectal cancer, this study validates the effectiveness of the logistic regression model in stool-based screening programmes. The random forest model did not improve the predictive performance, potentially due to the limited number of variables. Logistic regression remains the preferred prediction tool due to its interpretability.

INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Analysis of a machine learning-based risk stratification scheme for acute kidney injury in vancomycin

Fei Mu, Chen Cui, Meng Tang, Guiping Guo, Haiyue Zhang, Jie Ge, Yujia Bai, Jinyi Zhao, Shanshan Cao, Jingwen Wang, Yue Guan

Summary: This study aimed to construct a machine learning framework for stratified predicting and interpreting vancomycin-associated acute kidney injury (AKI). By analyzing the medical records of 724 patients, the study developed risk prediction models for different underlying diseases. The study also identified some underappreciated risk factors.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

SEER-based risk stratification system for patients with primary non-cirrhotic liver cancer

Runmin Cao, Honghe Jiang, Guangpeng Liang, Weibin Zhang

Summary: This study developed and validated a nomogram and risk stratification system to evaluate overall survival in non-cirrhotic hepatocellular carcinoma patients. Independent prognostic indicators included AFP levels, surgical intervention, T-stage, tumor size, and M-stage. The nomogram showed better prognostic accuracy compared to the AJCC staging system.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study

Laura Perez-Fernandez, Julia Sastre, Carles Zafon, Amelia Oleaga, Esmeralda Castelblanco, Ismael Capel, Juan C. Galofre, Sonsoles Guadalix-Iglesias, Antonio De la Vieja, Garcilaso Riesco-Eizaguirre

Summary: Dynamic risk stratification (DRS) is a new system in thyroid cancer that considers treatment response to improve the initial risk of recurrence. In this multicenter study, we validated the DRS system and found that integrating BRAFV600E into DRS does not provide additional benefit.

FRONTIERS IN ENDOCRINOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte

Chunguang Yang, Zhenghao Liu, Yin Fang, Xinyu Cao, Guoping Xu, Zhihua Wang, Zhiquan Hu, Shaogang Wang, Xinglong Wu

Summary: A clinic-ML nomogram was developed using functional subsets of peripheral lymphocyte to predict risk stratifications in prostate cancer. The nomogram showed superior performance compared to other models and can provide valuable information for individual diagnosis and treatment in PCa patients.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Development, validation, and evaluation of a risk assessment tool for personalized screening of gastric cancer in Chinese populations

Xia Zhu, Jun Lv, Meng Zhu, Caiwang Yan, Bin Deng, Canqing Yu, Yu Guo, Jing Ni, Qiang She, Tianpei Wang, Jiayu Wang, Yue Jiang, Jiaping Chen, Dong Hang, Ci Song, Xuefeng Gao, Jian Wu, Juncheng Dai, Hongxia Ma, Ling Yang, Yiping Chen, Mingyang Song, Qingyi Wei, Zhengming Chen, Zhibin Hu, Hongbing Shen, Yanbing Ding, Liming Li, Guangfu Jin

Summary: We developed a questionnaire-based tool to assess the risk of gastric cancer in the Chinese population and validated its effectiveness. The tool categorized participants into low, intermediate, and high-risk groups and successfully identified 81.6% of gastric cancer cases in the high-risk group.

BMC MEDICINE (2023)

Add to Collection

Editorial Material Hematology

International Consensus Classification for myeloid neoplasms at-a-glance

Attilio Orazi, Robert P. Hasserjian, Mario Cazzola, Hartmut Dohner, Ayalew Tefferi, Daniel A. Arber

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Mueller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Sator Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maclejewski, Seishi Ogawa

Summary: DDX41 gene mutations play an important role in late-onset myeloid neoplasms, but many crucial features of DDX41-mutated neoplasms still need to be elucidated. This study comprehensively characterized DDX41-mutated neoplasms and found that DDX41 risk variants accounted for 80% of known genetic predispositions to myeloid neoplasms in adults. Additionally, DDX41 risk alleles were significantly enriched in Japanese cases and more prominent in males compared to females.

BLOOD (2023)

Add to Collection

Review Oncology

Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations

Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, Attilio Guarini, Adalberto Ibatici, Stefano Luminari, Malgorzata Mikulska, Carlo Visco

Summary: This review provides the latest data on patients with lymphoma and COVID-19, and discusses practical guidance from diagnosis to follow-up. Lymphoma patients are at a higher risk of severe COVID-19 and may not be fully protected by vaccination. Passive immunization with monoclonal antibodies and antiviral drugs have shown effectiveness in managing lymphoma patients with COVID-19.

HEMATOLOGICAL ONCOLOGY (2023)

Add to Collection

Article Hematology

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Christian Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, Amandine Tisserand, Audrey Nedelec, Didier Vertommen, Anita Roy, Caroline Marty, Harini Nivarthi, Mira El-Khoury, Eva Hug, Andrea Majoros, Erica Xu, Oleh Zagrijtschuk, Tudor E. Fertig, Daciana S. Marta, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Roman Lesyk, Veronika Buxhofer-Ausch, Sonja Heibl, Florence Pasquier, Violaine Havelange, Isabell Plo, William Vainchenker, Robert Kralovics, Stefan N. Constantinescu

Summary: Mutant CALR proteins bind to and activate the TpoR in cells, driving the development of myeloproliferative neoplasms. These mutant CALR proteins can be found in patient plasma complexed with sTFR1, which increases their stability. They can specifically interact with TpoR on target cells and promote thrombopoietin-independent colony formation.

BLOOD (2023)

Add to Collection

Article Hematology

Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi

Annalisa Arcari, Valentina Tabanelli, Francesco Merli, Luigi Marcheselli, Michele Merli, Monica Balzarotti, Vittorio Ruggero Zilioli, Alberto Fabbri, Federica Cavallo, Gloria Margiotta Casaluci, Alessandra Tucci, Benedetta Puccini, Elsa Pennese, Alice Di Rocco, Manuela Zanni, Leonardo Flenghi, Guido Gini, Roberto Sartori, Annalisa Chiappella, Sara Veronica Usai, Monica Tani, Dario Marino, Luca Arcaini, Daniele Vallisa, Michele Spina

Summary: Up to 10%-15% of DLBCL cases in elderly patients are related to HCV infection. HCV+ patients were older, less fit, and had frequent extranodal involvement compared to HCV- patients. The use of DAAs in HCV+ patients showed good tolerance and a positive impact on progression-free survival.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Introduction to a review series on germ line predisposition to hematologic malignancies: time to consider germ line testing

Mario Cazzola

BLOOD (2023)

Add to Collection

Article Biochemistry & Molecular Biology

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli

Summary: Castleman disease (CD) is a rare lymphoproliferative disorder with various clinico-pathological subtypes. The pathogenesis of CD is still uncertain, but alterations in T-cell subsets may contribute to the development of CD. In this study, the distribution of T-cell subsets in the clinico-pathological spectrum of CD was investigated. The results showed decreased CD4/CD8 ratio and lower number of FOXP3+ T-reg cells in CD cases compared to non-specific reactive lymph nodes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-Garcia, Claire Harrison, Vikas Gupta

Summary: In patients with myelofibrosis who are naive to JAKi treatment, the rational combination of the BET inhibitor pelabresib and ruxolitinib showed good tolerability and durable improvements in spleen and symptom burden.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas

Marco Lucioni, Sara Fraticelli, Giovanni Santacroce, Arturo Bonometti, Nicola Aronico, Roberta Sciarra, Marco Vincenzo Lenti, Paola Ilaria Bianchi, Giuseppe Neri, Monica Feltri, Benedetto Neri, Giuseppina Ferrario, Roberta Riboni, Gino Roberto Corazza, Alessandro Vanoli, Luca Arcaini, Marco Paulli, Antonio Di Sabatino

Summary: This retrospective study aimed to describe the clinical-pathological characteristics of intestinal T-cell lymphomas (ITCL) and possibly identify their hallmarks. The study included 28 patients, with most cases associated with celiac disease. The presence of CD, peripheral lymphocytosis, advanced Lugano clinical stage, and the histological subtype ITCL-NOS were significantly associated with worse survival.

CANCERS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia Zappasodi

Summary: The combination of hypomethylating agents (HMA) azacytidine or decitabine with venetoclax (VEN) has been approved by the FDA for the treatment of acute myeloid leukemia (AML) patients aged over 75 years and those unsuitable for intensive chemotherapy. To prevent fungal infection during the early phase of treatment, posaconazole (PCZ) is commonly administered as primary prophylaxis. 165 plasma samples from 11 elderly AML patients receiving combined treatment with HMA, VEN, and PCZ were analyzed to determine the serum levels of venetoclax and the need for therapeutic drug monitoring due to high inter-individual variability in pharmacokinetics.

PHARMACEUTICS (2023)

Add to Collection

Article Microbiology

Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study

Valentina Zuccaro, Greta Petazzoni, Irene Mileto, Marta Corbella, Erika Asperges, Paolo Sacchi, Sara Rattotti, Marzia Varettoni, Irene Defrancesco, Patrizia Cambieri, Fausto Baldanti, Luca Arcaini, Raffaele Bruno

Summary: Several studies have shown a strong connection between gut microbiota and the response to immunotherapy in tumor patients, suggesting that gut microbiota can serve as a biomarker for response. This study aimed to compare the gut microbiota diversity in chronic lymphocytic leukemia patients treated with B-cell receptor inhibitors for at least 12 months. The findings revealed differences in bacterial distribution between different response groups.

MICROORGANISMS (2023)

Add to Collection

Editorial Material Hematology

Deciphering molecular complexity of HCV-associated lymphoproliferation

Michele Merli, Francesco Passamonti, Luca Arcaini

Summary: Recent clinical studies have shown that patients with Hepatitis C virus-associated indolent lymphoproliferative disorders (LPD) can achieve lymphoma responses when treated solely with direct-acting antivirals (DAAs). However, the molecular mechanisms underlying LPD responses to DAAs are not well understood. In this paper, the authors provide new molecular insights, reporting intraclonal diversification and persistence of B-cell clones in most cases, even after viral eradication and positive clinical outcomes. These findings suggest that achieving a molecular response may not be necessary for a 'functional cure' in these patients. Further immunogenetic and mutational studies are needed to better understand this biological puzzle and refine treatment strategies.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Early treatment for COVID-19 in patients with haematological malignancies: Much more than a recommendation!

Francesco Passamonti, Alessandra Bandera

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis

Francesco Passamonti, Youbei Lou, Manoj Chevli, Pranav Abraham

Summary: This observational study evaluated the outcomes of US myelofibrosis patients who received ruxolitinib treatment, and found that subsequent treatment with fedratinib led to improved survival compared to non-fedratinib treatment.

FUTURE ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.